Re-Purposing FDA-Approved Drugs for Opioid Use Disorder

References

• Adamson, S. J., Douglas Sellman, J., Foulds, J. A., Frampton, C. M., Deering, D., Dunn, A., Berks, J., Nixon, L., & Cape, G. (2015). A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression. Journal of Clinical Psychopharmacology, 35(2), 143–149. https://doi.org/10.1097/JCP.0000000000000287
   PubMed Web of Science ®Google Scholar
• Agabio, R., Campesi, I., Pisanu, C., Gessa, G. L., & Franconi, F. (2016). Sex differences in substance use disorders: Focus on side effects. Addiction Biology, 21(5), 1030–1042. https://doi.org/10.1111/adb.12395
   PubMed Web of Science ®Google Scholar
• Brady, K. T., & Verduin, M. L. (2005). Pharmacotherapy of comorbid mood, anxiety, and substance use disorders. Substance Use & Misuse, 40(13-14), 2021–2041. https://doi.org/10.1080/10826080500294924
   PubMed Web of Science ®Google Scholar
• Brown, E. S., Davila, D., Nakamura, A., Carmody, T. J., Rush, A. J., Lo, A., Holmes, T., Adinoff, B., Caetano, R., Swann, A. C., Sunderajan, P., & Bret, M. E. (2014). A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence. Alcoholism, Clinical and Experimental Research, 38(7), 2113–2118. https://doi.org/10.1111/acer.12445
   PubMed Web of Science ®Google Scholar
• Brown, E. S., Garza, M., & Carmody, T. J. (2008). A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders. The Journal of Clinical Psychiatry, 69(5), 701–705. https://doi.org/10.4088/JCP.v69n0502
   PubMed Web of Science ®Google Scholar
• Bschor, T. (2014). Lithium in the treatment of major depressive disorder. Drugs, 74(8), 855–862. https://doi.org/10.1007/s40265-014-0220-x
   PubMed Web of Science ®Google Scholar
• Charney, D. A., Heath, L. M., Zikos, E., Palacios-Boix, J., & Gill, K. J. (2015). Poorer drinking outcomes with citalopram treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism, Clinical and Experimental Research, 39(9), 1756–1765. https://doi.org/10.1111/acer.12802
   PubMed Web of Science ®Google Scholar
• Chen, L., Huang, S., Yang, C., Wu, F., Zheng, Q., Yan, H., Yan, J., Luo, Y., & Galaj, E. (2021). Blockade of β-adrenergic receptors by propranolol disrupts reconsolidation of drug memory and attenuates heroin seeking. Frontiers in Pharmacology, 12, 686845. https://doi.org/10.3389/fphar.2021.686845
   PubMed Web of Science ®Google Scholar
• Cruz-Burgos, M., Losada-Garcia, A., Cruz-Hernández, C. D., Cortés-Ramírez, S. A., Camacho-Arroyo, I., Gonzalez-Covarrubias, V., Morales-Pacheco, M., Trujillo-Bornios, S. I., & Rodríguez-Dorantes, M. (2021). New approaches in oncology for repositioning drugs: The case of PDE5 inhibitor sildenafil. Frontiers in Oncology, 11, 627229. https://doi.org/10.3389/fonc.2021.627229
   PubMed Web of Science ®Google Scholar
• Degenhardt, L., Larney, S., Kimber, J., Farrell, M., & Hall, W. (2015). Excess mortality among opioid-using patients treated with oral naltrexone in Australia. Drug and Alcohol Review, 34(1), 90–96. https://doi.org/10.1111/dar.12205
   PubMed Web of Science ®Google Scholar
• Evans, C. J., & Cahill, C. M. (2016). Neurobiology of opioid dependence in creating addiction vulnerability. F1000Res, 5 https://doi.org/10.12688/f1000research.8369.1
   Google Scholar
• US FDA. (2018). CIII highlights of prescribing information these highlights do not include all the information needed to use SUBUTEX ® safely and effectively. See full prescribing information for SUBUTEX. SUBUTEX (Buprenorphine Sublingual Tablets) for sublingual administration. Indivior Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020732s018lbl.pdf.
   Google Scholar
• US FDA. (2019). BUPRENEX ® (Buprenorphine Hydrochloride).
   Google Scholar
• Fox, H. C., Anderson, G. M., Tuit, K., Hansen, J., Kimmerling, A., Siedlarz, K. M., Morgan, P. T., & Sinha, R. (2012). Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: Preliminary findings. Alcoholism, Clinical and Experimental Research, 36(2), 351–360. https://doi.org/10.1111/j.1530-0277.2011.01628.x
   PubMed Web of Science ®Google Scholar
• Gadh, S. (2020). Low-dose lithium impact in an addiction treatment setting. Personalized Medicine in Psychiatry, 21-22, 100059. https://doi.org/10.1016/j.pmip.2020.100059
   Google Scholar
• Geller, B., Cooper, T. B., Sun, K., Zimerman, B., Frazier, J., Williams, M., & Heath, J. (1998). Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. Journal of the American Academy of Child and Adolescent Psychiatry, 37(2), 171–178. https://doi.org/10.1097/00004583-199802000-00009
   PubMed Web of Science ®Google Scholar
• George, T. P., Ziedonis, D. M., Feingold, A., Pepper, W. T., Satterburg, C. A., Winkel, J., Rounsaville, B. J., & Kosten, T. R. (2000). Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. The American Journal of Psychiatry, 157(11), 1835–1842. https://doi.org/10.1176/appi.ajp.157.11.1835
   PubMed Web of Science ®Google Scholar
• Greenwell, T. N., Walker, B. M., Cottone, P., Zorrilla, E. P., & Koob, G. F. (2009). The alpha1 adrenergic receptor antagonist prazosin reduces heroin self-administration in rats with extended access to heroin administration. Pharmacology, Biochemistry, and Behavior, 91(3), 295–302. https://doi.org/10.1016/j.pbb.2008.07.012
   PubMed Web of Science ®Google Scholar
• Grella, C. E., Hser, Y. I., Joshi, V., & Rounds-Bryant, J. (2001). Drug treatment outcomes for adolescents with comorbid mental and substance use disorders. The Journal of Nervous and Mental Disease, 189(6), 384–392. https://doi.org/10.1097/00005053-200106000-00006
   PubMed Web of Science ®Google Scholar
• Hadland, S. E., Bagley, S. M., Rodean, J., Silverstein, M., Levy, S., Larochelle, M. R., Samet, J. H., & Zima, B. T. (2018). Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder. JAMA Pediatrics, 172(11), 1029–1037. https://doi.org/10.1001/jamapediatrics.2018.2143
   PubMed Web of Science ®Google Scholar
• Haney, M., Hart, C. L., Vosburg, S. K., Comer, S. D., Reed, S. C., & Foltin, R. W. (2008). Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology, 197(1), 157–168. https://doi.org/10.1007/s00213-007-1020-8
   PubMed Web of Science ®Google Scholar
• Hanley, M. J., & Kenna, G. A. (2008). Quetiapine: Treatment for substance abuse and drug of abuse. American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists, 65(7), 611–618. https://doi.org/10.2146/ajhp070112
   PubMed Web of Science ®Google Scholar
• Hser, Y. I., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., Cohen, A., & Ling, W. (2014). Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction (Abingdon, England), 109(1), 79–87. https://doi.org/10.1111/add.12333
   PubMed Web of Science ®Google Scholar
• Hyttel, J. (1993). Comparative pharmacology of selective serotonin re-uptake inhibitors (SSRIs). Nordic Journal of Psychiatry, 47(sup30), 5–12. https://doi.org/10.3109/08039489309104119
   Google Scholar
• Johnston, J. A., Ascher, J., Leadbetter, R., Schmith, V. D., Patel, D. K., Durcan, M., & Bentley, B. (2002). Pharmacokinetic Optimisation of Sustained-Release Bupropion for Smoking Cessation. Drugs, 62 Suppl 2, 11–24. https://doi.org/10.2165/00003495-200262002-00002
   PubMed Web of Science ®Google Scholar
• Jones, C. M., & McCance-Katz, E. F. (2019). Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug and Alcohol Dependence, 197, 78–82. https://doi.org/10.1016/j.drugalcdep.2018.12.030
   PubMed Web of Science ®Google Scholar
• Kelly, T. M., & Daley, D. C. (2013). Integrated treatment of substance use and psychiatric disorders. Social Work in Public Health, 28(3-4), 388–406. https://doi.org/10.1080/19371918.2013.774673
   PubMed Web of Science ®Google Scholar
• Kelly, T. M., Daley, D. C., & Douaihy, A. B. (2012). Treatment of substance abusing patients with comorbid psychiatric disorders. Addictive Behaviors, 37(1), 11–24. https://doi.org/10.1016/j.addbeh.2011.09.010
   PubMed Web of Science ®Google Scholar
• Kessler, R. C., Chiu, W. T., Demler, O., Merikangas, K. R., & Walters, E. E. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62(6), 617–627. https://doi.org/10.1001/archpsyc.62.6.617
   PubMed Web of Science ®Google Scholar
• Kimber, J., Larney, S., Hickman, M., Randall, D., & Degenhardt, L. (2015). Mortality risk of opioid substitution therapy with methadone versus buprenorphine: A retrospective cohort study. The Lancet. Psychiatry, 2(10), 901–908. https://doi.org/10.1016/S2215-0366(15)00366-1
   PubMed Web of Science ®Google Scholar
• Klassen, T. P., Belseck, E. M., Wiebe, N., & Hartling, L. (2001). Acyclovir for treating varicella in otherwise healthy children and adolescents. Cochrane Database of Systematic Reviews, 2005(4):CD002980.
   Google Scholar
• Knackstedt, L. A., Melendez, R. I., & Kalivas, P. W. (2010). Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biological Psychiatry, 67(1), 81–84. https://doi.org/10.1016/j.biopsych.2009.07.018
   PubMed Web of Science ®Google Scholar
• Koob, G. F. (2020). Neurobiology of Opioid Addiction: Opponent Process, Hyperkatifeia, and Negative Reinforcement. Biological Psychiatry, 87(1), 44–53. https://doi.org/10.1016/j.biopsych.2019.05.023
   PubMed Web of Science ®Google Scholar
• Koob, G. F., & Schulkin, J. (2019). Addiction and stress: An allostatic view. Neuroscience and Biobehavioral Reviews, 106, 245–262. https://doi.org/10.1016/j.neubiorev.2018.09.008
   PubMed Web of Science ®Google Scholar
• Koob, G. F., & Le Moal, M. (2008). Neurobiological mechanisms for opponent motivational processes in addiction. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 363(1507), 3113–3123. https://doi.org/10.1098/rstb.2008.0094
   PubMed Web of Science ®Google Scholar
• Kosten, T. R., & Baxter, L. E. (2019). Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment. The American Journal on Addictions, 28(2), 55–62. https://doi.org/10.1111/ajad.12862
   PubMed Web of Science ®Google Scholar
• Kremer, M., Megat, S., Bohren, Y., Wurtz, X., Nexon, L., Ceredig, R. A., Doridot, S., Massotte, D., Salvat, E., Yalcin, I., & Barrot, M. (2020). Delta opioid receptors are essential to the antiallodynic action of B(2)-mimetics in a model of neuropathic pain. Molecular Pain, 16, 1744806920912931. https://doi.org/10.1177/1744806920912931
   Web of Science ®Google Scholar
• Lähteenvuo, M., Luykx, J. J., Taipale, H., Mittendorfer-Rutz, E., Tanskanen, A., Batalla, A., & Tiihonen, J. (2022). Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: Real-world evidence from two national cohorts. The British Journal of Psychiatry: The Journal of Mental Science, 221(6), 758–765. https://doi.org/10.1192/bjp.2022.117
   PubMed Web of Science ®Google Scholar
• Lopes, L. F., & Bacchi, C. E. (2010). Imatinib treatment for gastrointestinal stromal tumour (GIST). Journal of Cellular and Molecular Medicine, 14(1-2), 42–50. https://doi.org/10.1111/j.1582-4934.2009.00983.x
   PubMed Web of Science ®Google Scholar
• Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane Database of Systematic Reviews, (2), Cd002207. https://doi.org/10.1002/14651858.CD002207.pub4
   PubMed Web of Science ®Google Scholar
• McHugh, R. K., Votaw, V. R., Sugarman, D. E., & Greenfield, S. F. (2018). Sex and gender differences in substance use disorders. Clinical Psychology Review, 66, 12–23. https://doi.org/10.1016/j.cpr.2017.10.012
   PubMed Web of Science ®Google Scholar
• Morgan, J. R., Schackman, B. R., Leff, J. A., Linas, B. P., & Walley, A. Y. (2018). Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. Journal of Substance Abuse Treatment, 85, 90–96. https://doi.org/10.1016/j.jsat.2017.07.001
   PubMed Web of Science ®Google Scholar
• Moss, H. B., Chen, C. M., & Yi, H. Y. (2012). Measures of substance consumption among substance users, DSM-IV abusers, and those with DSM-IV dependence disorders in a nationally representative sample. Journal of Studies on Alcohol and Drugs, 73(5), 820–828. https://doi.org/10.15288/jsad.2012.73.820
   PubMed Web of Science ®Google Scholar
• Murthy, P., Mahadevan, J., & Chand, P. K. (2019). Treatment of substance use disorders with co-occurring severe mental health disorders. Current Opinion in Psychiatry, 32(4), 293–299. https://doi.org/10.1097/YCO.0000000000000510
   PubMed Web of Science ®Google Scholar
• Nejtek, V. A., Avila, M., Chen, L. A., Zielinski, T., Djokovic, M., Podawiltz, A., Kaiser, K., Bae, S., & Rush, A. J. (2008). Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial. The Journal of Clinical Psychiatry, 69(8), 1257–1266. https://doi.org/10.4088/jcp.v69n0808
   PubMed Web of Science ®Google Scholar
• O’Brien, C. P. (1996). Recent developments in the pharmacotherapy of substance abuse. Journal of Consulting and Clinical Psychology, 64(4), 677–686. https://doi.org/10.1037//0022-006x.64.4.677
   PubMed Web of Science ®Google Scholar
• O’Brien, C. P., Greenstein, R., & Woody, G. E. (1978). Update of naltrexone treatment. NIDA Research Monograph, (19), 315–320.
   PubMedGoogle Scholar
• O’Donnell, J. K., Gladden, R. M., & Seth, P. (2017). Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by Census Region—United States, 2006–2015." In Morbidity and Mortality Weekly Report. U.S. Department of Health and Human Services: Center for Disease Control and Prevention.
   Google Scholar
• Plewig, G., Petrozzi, J. W., & Berendes, U. (1970). Double-blind study of doxycycline in acne vulgaris. Archives of Dermatology, 101(4), 435–438. https://doi.org/10.1001/archderm.1970.04000040057011
   PubMedGoogle Scholar
• Polcin, D. L. (2016). Co-occurring substance abuse and mental health problems among homeless persons: Suggestions for research and practice. Journal of Social Distress and the Homeless, 25(1), 1–10. https://doi.org/10.1179/1573658X15Y.0000000004
   PubMed Web of Science ®Google Scholar
• Pradhan, A. A., Befort, K., Nozaki, C., Gavériaux-Ruff, C., & Kieffer, B. L. (2011). The delta opioid receptor: An evolving target for the treatment of brain disorders. Trends in Pharmacological Sciences, 32(10), 581–590. https://doi.org/10.1016/j.tips.2011.06.008
   PubMed Web of Science ®Google Scholar
• Preuss, U. W., Schaefer, M., Born, C., & Grunze, H. (2021). Bipolar disorder and comorbid use of illicit substances. Medicina (Kaunas), 57, 1256. https://doi.org/10.3390/medicina57111256
   PubMed Web of Science ®Google Scholar
• Resnick, R. B., Kestenbaum, R. S., Schwartz, L. K., & Smith, A. (1976). Evaluation of propranolol in opiate dependence. Archives of General Psychiatry, 33(8), 993–997. https://doi.org/10.1001/archpsyc.1976.01770080111011
   PubMed Web of Science ®Google Scholar
• Rudd, R. A., Aleshire, N., Zibbell, J. E., & Gladden, R. M. (2016). Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR. Morbidity and Mortality Weekly Report, 64(50-51), 1378–1382. https://doi.org/10.15585/mmwr.mm6450a3
   PubMed Web of Science ®Google Scholar
• SAMHSA. (2023). Co-occurring disorders and other health conditions, SAMSHSA.gov. https://www.samhsa.gov/medications-substance-use-disorders/medications-counseling-related-conditions/co-occurring-disorders
   Google Scholar
• Sani, G., Kotzalidis, G. D., Vöhringer, P., Pucci, D., Simonetti, A., Manfredi, G., Savoja, V., Tamorri, S. M., Mazzarini, L., Pacchiarotti, I., Telesforo, C. L., Ferracuti, S., Brugnoli, R., Ambrosi, E., Caloro, M., Del Casale, A., Koukopoulos, A. E., Vergne, D. E., Girardi, P., & Ghaemi, S. N. (2013). Effectiveness of short-term olanzapine in patients with bipolar i disorder, with or without comorbidity with substance use disorder. Journal of Clinical Psychopharmacology, 33(2), 231–235. https://doi.org/10.1097/JCP.0b013e318287019c
   PubMed Web of Science ®Google Scholar
• Schainker, L. M., Voss, M. W., & Yaugher, A. C. (2021). Integrated care approach to the prevention of opioid use disorder. In W. O’Donohue and M. Zimmermann (Eds.), Handbook of Evidence-Based Prevention of Behavioral Disorders in Integrated Care: A Stepped Care Approach Springer International Publishing.
   Google Scholar
• Sheidow, A. J., McCart, M., Zajac, K., & Davis, M. (2012). Prevalence and impact of substance use among emerging adults with serious mental health conditions. Psychiatric Rehabilitation Journal, 35(3), 235–243. https://doi.org/10.2975/35.3.2012.235.243
   PubMed Web of Science ®Google Scholar
• Silvestre, J. S., & Prous, J. (2005). Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol, 27, 289–304.
   PubMed Web of Science ®Google Scholar
• Sinha, R., Shaham, Y., & Heilig, M. (2011). Translational and reverse translational research on the role of stress in drug craving and relapse. Psychopharmacology, 218(1), 69–82. https://doi.org/10.1007/s00213-011-2263-y
   PubMed Web of Science ®Google Scholar
• Solomon, R. L., & Corbit, J. D. (1973). An opponent-process theory of motivation: II. Cigarette addiction. Journal of Abnormal Psychology, 81(2), 158–171. https://doi.org/10.1037/h0034534
   PubMed Web of Science ®Google Scholar
• Stedman, M., Pettinati, H. M., Brown, E. S., Kotz, M., Calabrese, J. R., & Raines, S. (2010). A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence. Alcoholism, Clinical and Experimental Research, 34(10), 1822–1831. https://doi.org/10.1111/j.1530-0277.2010.01270.x
   PubMed Web of Science ®Google Scholar
• Suchting, R., Green, C. E., de Dios, C., Vincent, J., Gerard Moeller, F., Lane, S. D., & Schmitz, J. M. (2021). Citalopram for treatment of cocaine use disorder: A Bayesian drop-the-loser randomized clinical trial. Drug and Alcohol Dependence, 228, 109054. https://doi.org/10.1016/j.drugalcdep.2021.109054
   PubMed Web of Science ®Google Scholar
• Teo, S. K., Resztak, K. E., Scheffler, M. A., Kook, K. A., Zeldis, J. B., Stirling, D. I., & Thomas, S. D. (2002). Thalidomide in the treatment of leprosy. Microbes and Infection, 4(11), 1193–1202. https://doi.org/10.1016/s1286-4579(02)01645-3
   PubMed Web of Science ®Google Scholar
• Timko, C., Schultz, N. R., Cucciare, M. A., Vittorio, L., & Garrison-Diehn, C. (2016). Retention in medication-assisted treatment for opiate dependence: A systematic review. Journal of Addictive Diseases, 35(1), 22–35. https://doi.org/10.1080/10550887.2016.1100960
   PubMed Web of Science ®Google Scholar
• Simpson, T. L., Saxon, A. J., Stappenbeck, C., Malte, C. A., Lyons, R., Tell, D., Millard, S. P., & Raskind, M. (2018). Double-blind randomized clinical trial of prazosin for alcohol use disorder. The American Journal of Psychiatry, 175(12), 1216–1224. PhD PhD MSW ARNP PhD M.D. https://doi.org/10.1176/appi.ajp.2018.17080913
   PubMed Web of Science ®Google Scholar
• Trivedi, M. H., Walker, R., Ling, W., Dela Cruz, A., Sharma, G., Carmody, T., Ghitza, U. E., Wahle, A., Kim, M., Shores-Wilson, K., Sparenborg, S., Coffin, P., Schmitz, J., Wiest, K., Bart, G., Sonne, S. C., Wakhlu, S., Rush, A. J., Nunes, E. V., & Shoptaw, S. (2021). Bupropion and naltrexone in methamphetamine use disorder. The New England Journal of Medicine, 384(2), 140–153. https://doi.org/10.1056/NEJMoa2020214
   PubMed Web of Science ®Google Scholar
• Vasilenko, S. A., Evans-Polce, R. J., & Lanza, S. T. (2017). Age trends in rates of substance use disorders across ages 18-90: Differences by gender and race/ethnicity. Drug and Alcohol Dependence, 180, 260–264. https://doi.org/10.1016/j.drugalcdep.2017.08.027
   PubMed Web of Science ®Google Scholar
• Watanabe, T., Nakagawa, T., Yamamoto, R., Maeda, A., Minami, M., & Satoh, M. (2003). Involvement of noradrenergic system within the central nucleus of the amygdala in naloxone-precipitated morphine withdrawal-induced conditioned place aversion in rats. Psychopharmacology, 170(1), 80–88. https://doi.org/10.1007/s00213-003-1504-0
   PubMed Web of Science ®Google Scholar
• Woolf, B. (1955). On estimating the relation between blood group and disease. Annals of Human Genetics, 19(4), 251–253. https://doi.org/10.1111/j.1469-1809.1955.tb01348.x
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2003). Adherence to long-term therapies: Evidence for action. World Health Organization.
   Google Scholar
• Wu, Y., Li, Y., Yang, X., & Sui, N. (2014). Differential effect of beta-adrenergic receptor antagonism in basolateral amygdala on reconsolidation of aversive and appetitive memories associated with morphine in rats. Addiction Biology, 19(1), 5–15. https://doi.org/10.1111/j.1369-1600.2012.00443.x
   PubMed Web of Science ®Google Scholar
• Yamamoto, A., Needleman, J., Gelberg, L., Kominski, G., Shoptaw, S., & Tsugawa, Y. (2019). Association between homelessness and opioid overdose and opioid-related hospital admissions/emergency department visits. Social Science & Medicine (1982), 242, 112585. https://doi.org/10.1016/j.socscimed.2019.112585
   PubMed Web of Science ®Google Scholar
• Zhou, M., Wang, Q., Zheng, C., John Rush, A., Volkow, N. D., & Xu, R. (2021). Drug repurposing for opioid use disorders: Integration of computational prediction, clinical corroboration, and mechanism of action analyses. Molecular Psychiatry, 26(9), 5286–5296. https://doi.org/10.1038/s41380-020-01011-y
   PubMed Web of Science ®Google Scholar